CA9 and triple-negative breast carcinoma: However, even though their cytotoxicity was not very high, all four compounds were more active against the triple-negative breast cancer cell line MDA-MB-231 than CA-IX inhibitor U-104, and more active against all cell lines than the non-selective CA inhibitor acetazolamide.